In response to your basic logic. Yes 1 - the tech works in AUS in INDO, as too yet if it works properly in the US is yet to be determined. It might do and yes it might not as well and it was masked under the incorrect trial last time. MSF stopped using it. So what does that tell you. But thats the punt you take.
2 - big deal. Every director / CEO in every publicly listed company on the ASX has some sort of interest in their company. Wether or not it be through options or shares / performance incentives. They already give themselves a decent salary so the shares doing well just means they get more richer. They are already rich.
3 - see above. They are already better off by miles then a retail SH. Look at GSW for example. Those guys pay themselves a whack and look how useless they are.
RAP Price at posting:
10.5¢ Sentiment: Sell Disclosure: Not Held
